NCT03810794 Clinical Evaluation on the Therapeutic Effect of Acupuncture Treatment for Alzheimer's Disease
| NCT ID | NCT03810794 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jian Pei,MD |
| Condition | Alzheimer Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 180 participants |
| Start Date | 2019-03-01 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 180 participants in total. It began in 2019-03-01 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this proposed study is to evaluate the effect and safety of acupuncture combined therapy on cognitive function, daily living ability and quality of life of Alzheimer's disease by using the international dementia certification scale. In this 12-week, assessor-blind, a Multi-center randomized, controlled study of acupuncture as additional treatment with Donepezil, a total of 180 patients with Alzheimer's disease will be recruited. The patients will be randomly assigned to acupuncture combined with Donepezil (n =90) or Donepezil treatment (n =90). (36 sessions, 3 sessions a week). Changes in the cognition over time measured using ADAS-cog is the primary outcome. MMSE, ADCS-ADL and QOL-AD are the secondary outcomes. The study will be conducted at LongHua Hospital Shanghai University of Traditional Chinese Medicine, Huashan Hospital Fudan University, and Mental Health Center Shanghai Jiao Tong University School of Medicine.
Eligibility Criteria
Inclusion Criteria: * aged between 50-85 years * the diagnostic criteria of Neurological Communicative Disorders and Stroke and the Alzheimer Disease and Related Disorders Association (NINCDS-ADRDA) * cognitive impairment based on the scores of the Chinese version of the Mini Mental State Examination (MMSE) (patients with mild to moderate Alzheimers disease, 11≤primary school degree≤22, 11≤junior high school degree or above≤26 * magnetic resonance imaging (MRI) confirmation of atrophy of the hippocampus or the medial temporal lobe volume, MRI manifestation of high possibility of Alzheimer Disease * the Medial Temporal Lobe Atrophy Rating Scale (MTA-scale) score (≥2 for those under 75 years, and ≥3 for those over 75 years) * voluntarily joining this study with informed consents Exclusion Criteria: * cognitive impairment caused by other factors (e.g. vascular dementia, dementia with Lewy bodies, frontotemporal dementia, hormone or metabolic abnormalities, hypothyroidism, folic acid or vitamin B12 deficiency, delirium or other mental and emotional disorders (such as schizophrenia and depression)) * a serious heart condition, hepatic disease, renal system disease, hematopoietic system disease, or whole-body malnutrition * aphasia, disturbance of consciousness, or failure to cooperate with the related examinations due to physical disability * anticoagulant treatments such as warfarin or heparin * use of pacemakers or receiving acupuncture in the past 2 weeks
Contact & Investigator
Jian Pei, Doctor
STUDY CHAIR
Shanghai University of Traditional Chinese Medicine
Frequently Asked Questions
Who can join the NCT03810794 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 85 Years, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03810794 currently recruiting?
Yes, NCT03810794 is actively recruiting participants. Contact the research team at jianpei99@hotmail.com for enrollment information.
Where is the NCT03810794 trial being conducted?
This trial is being conducted at Shanghai, China, Shanghai, China, Shanghai, China.
Who is sponsoring the NCT03810794 clinical trial?
NCT03810794 is sponsored by Jian Pei,MD. The principal investigator is Jian Pei, Doctor at Shanghai University of Traditional Chinese Medicine. The trial plans to enroll 180 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.